Want to see CPIX full AI Analyst Report?
Total Valuation
Cumberland Pharmaceuticals has a market cap or net worth of $114.62M. The enterprise value is $97.60.
Market Cap$114.62M
Enterprise Value$97.60
Share Statistics
Cumberland Pharmaceuticals has 14,983,107 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,983,107
Owned by Insiders41.60%
Owned by Institutions4.34%
Financial Efficiency
Cumberland Pharmaceuticals’s return on equity (ROE) is -0.11 and return on invested capital (ROIC) is -6.89%.
Return on Equity (ROE)-0.11
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-6.89%
Return on Capital Employed (ROCE)-0.07
Revenue Per Employee478.73K
Profits Per Employee-30.80K
Employee Count93
Asset Turnover0.58
Inventory Turnover1.07
Valuation Ratios
The current PE Ratio of Cumberland Pharmaceuticals is ―. Cumberland Pharmaceuticals’s PEG ratio is 0.36.
PE Ratio―
PS Ratio1.34
PB Ratio2.39
Price to Fair Value2.39
Price to FCF12.31
Price to Operating Cash Flow149.81
PEG Ratio0.36
Income Statement
In the last 12 months, Cumberland Pharmaceuticals had revenue of 44.52M and earned -2.84M in profits. Earnings per share was -0.19.
Revenue44.52M
Gross Profit37.85M
Operating Income-2.79M
Pretax Income-2.82M
Net Income-2.84M
EBITDA2.96M
Earnings Per Share (EPS)-0.19
Cash Flow
In the last 12 months, operating cash flow was 750.05K and capital expenditures -114.37K, giving a free cash flow of 635.69K billion.
Operating Cash Flow750.05K
Free Cash Flow635.69K
Free Cash Flow per Share0.04
Dividends & Yields
Cumberland Pharmaceuticals pays an annual dividend of $1.5, resulting in a dividend yield of 18.48%
Dividend Per Share$1.5
Dividend Yield18.48%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.06
52-Week Price Change198.57%
50-Day Moving Average5.76
200-Day Moving Average3.62
Relative Strength Index (RSI)62.84
Average Volume (3m)27.29K
Important Dates
Cumberland Pharmaceuticals upcoming earnings date is Nov 10, 2026, After Close (Confirmed).
Last Earnings DateAug 4, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
Cumberland Pharmaceuticals as a current ratio of 1.01, with Debt / Equity ratio of 27.03%
Current Ratio1.01
Quick Ratio0.84
Debt to Market Cap0.09
Net Debt to EBITDA-0.43
Interest Coverage Ratio-5.63
Taxes
In the past 12 months, Cumberland Pharmaceuticals has paid 40.26K in taxes.
Income Tax40.26K
Effective Tax Rate-0.01
Enterprise Valuation
Cumberland Pharmaceuticals EV to EBITDA ratio is 19.70, with an EV/FCF ratio of 12.05.
EV to Sales1.31
EV to EBITDA19.70
EV to Free Cash Flow12.05
EV to Operating Cash Flow11.81
Balance Sheet
Cumberland Pharmaceuticals has $3.86M in cash and marketable securities with $4.71M in debt, giving a net cash position of -$851.78K billion.
Cash & Marketable Securities$3.86M
Total Debt$4.71M
Net Cash-$851.78K
Net Cash Per Share-$0.06
Tangible Book Value Per Share$0.64
Margins
Gross margin is 83.37%, with operating margin of -6.27%, and net profit margin of -6.37%.
Gross Margin83.37%
Operating Margin-6.27%
Pretax Margin-6.34%
Net Profit Margin-6.37%
EBITDA Margin6.64%
EBIT Margin-5.23%
Analyst Forecast
The average price target for Cumberland Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-25.68%
EPS Growth Forecast-244.92%